In this shorl term study, ATOR can down-regulate the expression of CD4OL and p-selectin on platelets in patients with HC. We also found that the level of TNF-a was correlated with VLDL and LDUHDL ratio. We supposed that in addition lo Its effect on decreasing the cholesterol level, ATOR can intervene the Interaction of CD40-CD40L and the expression of p-selectin whrch may alleviate the prothrombotic potency of platelets III patients with HC.
Conclusion:
In this shorl term study, ATOR can down-regulate the expression of CD4OL and p-selectin on platelets in patients with HC. We also found that the level of TNF-a was correlated with VLDL and LDUHDL ratio. We supposed that in addition lo Its effect on decreasing the cholesterol level, ATOR can intervene the Interaction of CD40-CD40L and the expression of p-selectin whrch may alleviate the prothrombotic potency of platelets III patients with HC.
1083-140
Ezetimibe ease, or multiple cardiovascular risk factors. Methods: After dietary stabilization, a 6-to IO-week washout. and ATOR run-I" oeriod fooen-label ATOR 10 moldav~. 621 oatients _ ,,.
with baseline LDL-C ~130 mg/dL and TG 1350 mg!dL on ATOR IO mg were randomized to two treatment arms; EZE 10 mg or addttional double-blind ATOR (IO mg) adminlstered daily for 4 weeks. The ATOR dose was doubled if LDL-C was >I00 mgldL afier 4 and/or 9 weeks of treatment (maximum 60 mglday with ATOR alone; 40 mg/day with coadmintstration). The primary endpoint was the proportton of patients achieving target LDL-C <lo0 mg/dL at week 14. Results: Addltlon of EZE to ATOR IO mglday followed by response-based titration of ATOR significantly increased the proportion of patients reaching target LDL-C to 22% (67/305) versus titration of ATOR alone of 7% (23/316; p<O.Ol). EZE+ATOR 10 mg significantly reduced LDL-C versus ATOR 20 mg at week 4 (22.6% versus 6.6%; p<O.Ol).
In addition, despite only 60% of subjects in the EZE+ATOR group being on ATOR 40 mg (none on 60 mg) and 65% of ATOR group on 60 mg. the final (week 14) LDL-C reduction from randomization was 31.2% versus l&9%, respectively. EZE+ATOR was well tolerated. with a safety profile similar to ATOR alone. Conclusion: Adding EZE to ongoing ATOR provides significantly greater LDL-C reduction than continued doubling of ATOR dose alone, and results in 3 times as many patients reaching target LDL-C. This offers a highly efficacious and well tolerated new treatment approach in hypercholeslerolemia.
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Heterozygous In HeFH patients, adding EZE to ATV provides significantly greater reduction in LDL-C and other lipid parameters than doubling the ATV'dose alone, and results in four times as many patients achieving target LDL-C. EZE + ATV offers a highly efficacious and well tolerated therapeutic approach in HeFH. IOmg was compared with Pbo + higher doses of statin alone (simvastatin (S) 60mg, atorvastatin (A) 6Omg. pravastatin (P) 40mg, or lovastatin (L) 40mg). After dietary stabilization @ NCEP Step I), a 2.12.wk screening/washout period and a 4.wk, Pbo lead-an period, pts with basekne LDL-C 2145 to <250 mgldl and TG 5350 mgldl were randomized to EZE + statin or Pbo + statin daily for 12 weeks.
1083-i 42
Results EZE + statin IOma resulted in similar LDL-C reductions as those achieved with higher doses of statins alone (table) and comparable or greater effects on HDL-C and TG cornoared lo statin monotheraw. The effects of EZE on LDL-C were indeoendent of the I statin tested. EZE had an excellent safety profile and was well tolerated.
Conclusiorr
The addition of EZE IO mg to low doses of statIns (IOmg) provides similar effects on LDL-C, HDL-C, and TG, compared to high-dose statin monotherapy (SBOmg, AEOmg, P40mg, L40mg). The addition of EZE to statins provides an alternatwe to highdose statins for therapy of hypercholesterolemla.
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